Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401148 | 1.00 | NPC1 (0.48) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL2402987 | 0.86 | KDM4E (0.51) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL2402980 | 0.86 | KDM4E (0.51) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL28198370 | 0.83 | — | — | |
| SCHEMBL12574025 | 0.77 | MEN1 (0.57) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL28171744 | 0.76 | MEN1 (0.47) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL14654943 | 0.76 | MAPT (0.45) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL5112007 | 0.75 | TSHR (0.59) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL3449454 | 0.75 | MEN1 (0.46) | NPC1MEN1KMT2ATSHREPHX2 | |
| SCHEMBL29587148 | 0.74 | MEN1 (0.44) | NPC1MEN1KMT2ATSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | NPC1 4514/4885MEN1 4124/4885KMT2A 1733/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | NPC1 4514/4885MEN1 4124/4885KMT2A 1733/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | NPC1 4514/4885MEN1 4124/4885KMT2A 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.